JM

Veldmar Therapeutics Ltd.

TSXV: VLDM

Pre-revenue oncology developer. Shares auditor and a scientific officer with Cascade BioSciences. Recently filed a bought-deal financing.

OverviewFlagsFilingsContradictionsRisksNetworkEnforcementInsider trades

Governance

Officers

  • Noor Haddad, M.D.CEO
  • Julien ArsenaultCFO

Board

  • Noor Haddad, M.D.
  • George Aalto
  • Mira Okonkwo
  • Priya Naidu, Ph.D.

Company facts

HQ
Toronto, ON
Regulator
OSC
Market cap
$96.4M
Incorporated
Feb 18, 2020

Corporate timeline

  1. Feb 18, 2020
    Incorporated under the Canada Business Corporations Act
    Incorporation

    Federal incorporation; Toronto head office.

  2. Oct 04, 2021
    Listed on the TSX Venture Exchange
    Listing

    $15M IPO at $1.75 per unit.

  3. Nov 04, 2024
    Priya Naidu appointed Independent Director
    Director Change

    Concurrent service as Cascade BioSciences CSO.

  4. Jun 18, 2026
    Closed $22M bought-deal financing
    Restructuring

    Extends runway through Q1 2027.

    ↳ SP-2026-06-18-VLDM-NR-44012

Auditor history

1
Ashford Whitman LLP
Feb 18, 2020 → Present

Original auditor; continuous tenure.